Dewan Roshan Singh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Dewan Roshan Singh has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
N Krishnaveni
Department of Anaesthesiology, Sri Venkateshwara Medical College and Research Institute, Puducherry, India
4 shared publicationsKusha Nag
Department of Anaesthesiology, Mahatma Gandhi Medical College, SBV University, Puducherry, India
3 shared publicationsAkshaya N Shetti
Department of Anaesthesiology and Critical Care, Mahatma Gandhi Medical College, Pillaiyarkuppam, Pondicherry, India
1 shared publicationAkshayaN Shetti
Department of Anaesthesiology, Krishna Institute of Medical Sciences, Karad, Maharashtra, India
1 shared publication- Antony John Charles
Sri Balaji Vidyapeeth (Deemed to be university), Puducherry
1 shared publication Hajer Mohamed
Department of Anaesthesiology, Mahatma Gandhi Medical College, SBV University, Puducherry, India
1 shared publication
Latest Publications
- Open Access
- 5 July 2017
- Published by Sri Lanka Journals Online in Sri Lankan Journal of Anaesthesiology
- Vol. 25 (2) , 76
Comparison of efficacy of intravenous dexmedetomidine with intravenous ketamine in allaying procedural discomfort during establishment of subarachnoid block
Background: Procedural discomfort is experienced by patients during the establishment of subarachnoid block even after good preoperative counseling and adequate premedication. The fear of needle prick, back pain during and after subarachnoid injection are becoming the leading causes for patient refusal to spinal anaesthesia. To enhance comfort and to overcome the denial, procedural sedation that would provide good analgesia, faster recovery and amnesia is inevitable. Materials and methods: Patients with ASA status I and II posted for elective surgeries under subarachnoid block were premedicated with midazolam 0.05mg/kg and pre-loaded with 10 ml/kg ringer lactate solution. They were randomized into 2 groups of 30 each. Group D received dexmedetomidine 1mcg/kg bolus over 10 min, group K received ketamine 0.3mg/kg intravenously. University of Michigan sedation score, ease of positioning, prick response, verbal response, hallucinations, recall of procedure and patient satisfaction were evaluated. Results: Both the drugs produced adequate sedation for performing subarachnoid block, UMSS score response to needle prick was comparable between them. Significant difference was observed during positioning the patient for subarachnoid block. Patients sedated with dexmedetomidine were able to position themselves without any help whereas patients sedated with ketamine required one or two persons help. In maintaining verbal response during the procedure both the drugs showed significant difference between them. In group D, most of the patients maintained the verbal response from immediately after bolus to throughout the study. Whereas in group K, no patient responded to verbal command after bolus up till 3min and majority of them (40%) regained verbal response only at 4min after bolus injection. There were no hallucinations and no recall of events in both groups. Except one patient in group D, all the patients were satisfied and willing to undergo subarachnoid block if need arises. Conclusion: We conclude that both ketamine and dexmedetomidine provided adequate sedoanalgesia for performing subarachnoid block. Dexmedetomidine was advantageous in terms of maintaining verbal response and ability to positioning themselves.
- 5 July 2017
- Published by Sri Lanka Journals Online in Sri Lankan Journal of Anaesthesiology
- Vol. 25 (2) , 76
Open AccessComparison of efficacy of intravenous dexmedetomidine with intravenous ketamine in allaying procedural discomfort during establishment of subarachnoid block
Background: Procedural discomfort is experienced by patients during the establishment of subarachnoid block even after good preoperative counseling and adequate premedication. The fear of needle prick, back pain during and after subarachnoid injection are becoming the leading causes for patient refusal to spinal anaesthesia. To enhance comfort and to overcome the denial, procedural sedation that would provide good analgesia, faster recovery and amnesia is inevitable. Materials and methods: Patients with ASA status I and II posted for elective surgeries under subarachnoid block were premedicated with midazolam 0.05mg/kg and pre-loaded with 10 ml/kg ringer lactate solution. They were randomized into 2 groups of 30 each. Group D received dexmedetomidine 1mcg/kg bolus over 10 min, group K received ketamine 0.3mg/kg intravenously. University of Michigan sedation score, ease of positioning, prick response, verbal response, hallucinations, recall of procedure and patient satisfaction were evaluated. Results: Both the drugs produced adequate sedation for performing subarachnoid block, UMSS score response to needle prick was comparable between them. Significant difference was observed during positioning the patient for subarachnoid block. Patients sedated with dexmedetomidine were able to position themselves without any help whereas patients sedated with ketamine required one or two persons help. In maintaining verbal response during the procedure both the drugs showed significant difference between them. In group D, most of the patients maintained the verbal response from immediately after bolus to throughout the study. Whereas in group K, no patient responded to verbal command after bolus up till 3min and majority of them (40%) regained verbal response only at 4min after bolus injection. There were no hallucinations and no recall of events in both groups. Except one patient in group D, all the patients were satisfied and willing to undergo subarachnoid block if need arises. Conclusion: We conclude that both ketamine and dexmedetomidine provided adequate sedoanalgesia for performing subarachnoid block. Dexmedetomidine was advantageous in terms of maintaining verbal response and ability to positioning themselves.
- Open Access
- 1 January 2017
- Published by Medknow in Anesthesia: Essays and Researches
- Vol. 11 (3) , 572-577
Evaluating the efficacy of tramadol as an adjuvant to intrathecal isobaric levobupivacaine for elective infraumbilical surgeries
Background: Long-acting local anesthetics are used in subarachnoid block to increase the duration of anesthesia. Adjuvants are added to improve the duration of analgesia. Settings: Randomized controlled trial was conducted in the Department of Anesthesiology in a tertiary care hospital.Aims and Objectives: The objective of this study was to evaluate the efficacy of low-dose tramadol as an intrathecal adjuvant to levobupivacaine in terms of duration of analgesia, onset of sensory blockade, onset of motor blockade, and duration of motor blockade. Methodology: After obtaining the Institutional Ethics Committee approval and informed consent, sixty patients posted for infraumbilical surgeries were recruited. Randomization was done using a sealed envelope technique. Patients were divided into two groups: LT received 3 ml of 0.5% isobaric levobupivacaine with tramadol 10 mg (0.2 ml) and LS received 3 ml of 0.5% isobaric levobupivacaine with 0.2 ml of normal saline. Duration of analgesia, onset of sensory blockade, and onset and duration of motor blockade were recorded. Results: There was no statistical difference in demographic data between the two groups. The mean onset time of sensory blockade in Group LS was 12.7 ± 9.81 min and for Group LT was 12.9 ± 0.81 min, which was not statistically significant between two groups (P = 0.93). The mean onset time of motor blockade in Group LS was 13.4 ± 10 min and for Group LT was 14.4 ± 10 min, which was no statistically significant between the two groups (P = 0.71). The mean time duration of analgesia in Group LS was 170.3 ± 59 min and for LT was 198.9 ± 57.33 min. There was mild prolongation of analgesia in Group LT, but it was not statistically significant (P = 0.0615). The mean duration of motor blockade in Group LS was 170.23 ± 58 min and Group LT was 190.76 ± 4 min, which was not statistically significant between the two groups (P = 0.14). Conclusion: Low-dose tramadol as an adjuvant to isobaric intrathecal levobupivacaine does not prolong analgesia significantly.
- 1 January 2017
- Published by Medknow in Anesthesia: Essays and Researches
- Vol. 11 (3) , 572-577
Open AccessEvaluating the efficacy of tramadol as an adjuvant to intrathecal isobaric levobupivacaine for elective infraumbilical surgeries
Background: Long-acting local anesthetics are used in subarachnoid block to increase the duration of anesthesia. Adjuvants are added to improve the duration of analgesia. Settings: Randomized controlled trial was conducted in the Department of Anesthesiology in a tertiary care hospital.Aims and Objectives: The objective of this study was to evaluate the efficacy of low-dose tramadol as an intrathecal adjuvant to levobupivacaine in terms of duration of analgesia, onset of sensory blockade, onset of motor blockade, and duration of motor blockade. Methodology: After obtaining the Institutional Ethics Committee approval and informed consent, sixty patients posted for infraumbilical surgeries were recruited. Randomization was done using a sealed envelope technique. Patients were divided into two groups: LT received 3 ml of 0.5% isobaric levobupivacaine with tramadol 10 mg (0.2 ml) and LS received 3 ml of 0.5% isobaric levobupivacaine with 0.2 ml of normal saline. Duration of analgesia, onset of sensory blockade, and onset and duration of motor blockade were recorded. Results: There was no statistical difference in demographic data between the two groups. The mean onset time of sensory blockade in Group LS was 12.7 ± 9.81 min and for Group LT was 12.9 ± 0.81 min, which was not statistically significant between two groups (P = 0.93). The mean onset time of motor blockade in Group LS was 13.4 ± 10 min and for Group LT was 14.4 ± 10 min, which was no statistically significant between the two groups (P = 0.71). The mean time duration of analgesia in Group LS was 170.3 ± 59 min and for LT was 198.9 ± 57.33 min. There was mild prolongation of analgesia in Group LT, but it was not statistically significant (P = 0.0615). The mean duration of motor blockade in Group LS was 170.23 ± 58 min and Group LT was 190.76 ± 4 min, which was not statistically significant between the two groups (P = 0.14). Conclusion: Low-dose tramadol as an adjuvant to isobaric intrathecal levobupivacaine does not prolong analgesia significantly.
- Open Access
- 1 January 2017
- Published by Medknow in Anesthesia: Essays and Researches
- Vol. 11 (3) , 567-571
Efficacy of tramadol or dexamethasone as an adjuvant to levobupivacaine in ultrasound-guided supraclavicular plexus block for upper limb surgery: A randomized double-blinded controlled study
Aims and Objectives: To evaluate the efficacy of tramadol or dexamethasone as an adjuvant to levobupivacaine in ultrasound-guided supraclavicular brachial plexus block in terms of onset time of complete sensory and motor blockade, duration of motor blockade, duration of analgesia, and any complication. Settings and Design: This was a randomized controlled trial conducted in the Department of Anesthesiology, a tertiary care hospital. Materials and Methods: Sixty consecutive patients of the American Society of Anesthesiologists physical status Class I and II who were posted for upper limb surgeries were recruited. Patients were divided into two groups of thirty patients each. Group T (tramadol) received 20 ml of 0.5% levobupivacaine with 100 mg tramadol, and Group D (dexamethasone) received 20 ml of 0.5% levobupivacaine with 8 mg dexamethasone under ultrasound guidance. Sensory and motor block assessment was done every 2 min until the development of complete sensory and motor block till 45 min. Verbal numerical rating scale score was assessed in postoperative ward at regular intervals. Patients were followed up to check for any residual neurological deficits. Results: There was no statistical difference in demographic data between the two groups. The onset time of sensory and motor blockade shows no significant difference between groups. The mean time duration of motor blockade in Group T was 764.63 min and for Group D was 1150.27 min which was statistically significant (P < 0.05). The duration of analgesia in Group D was 1300.83 min and in Group T was 820.47 min which was statistically significant (P < 0.05). Side effects such as nausea, vomiting, pruritis, hypoxemia, and long-term neurological deficits were not reported in any of the patients in either group. Conclusion: Dexamethasone 8 mg as an adjuvant to 0.5% levobupivacaine for supraclavicular brachial plexus block using ultrasound guidance increases the duration of analgesia in comparison to 100 mg tramadol and provides excellent postoperative pain-free period without any neurological deficits.
- 1 January 2017
- Published by Medknow in Anesthesia: Essays and Researches
- Vol. 11 (3) , 567-571
Open AccessEfficacy of tramadol or dexamethasone as an adjuvant to levobupivacaine in ultrasound-guided supraclavicular plexus block for upper limb surgery: A randomized double-blinded controlled study
Aims and Objectives: To evaluate the efficacy of tramadol or dexamethasone as an adjuvant to levobupivacaine in ultrasound-guided supraclavicular brachial plexus block in terms of onset time of complete sensory and motor blockade, duration of motor blockade, duration of analgesia, and any complication. Settings and Design: This was a randomized controlled trial conducted in the Department of Anesthesiology, a tertiary care hospital. Materials and Methods: Sixty consecutive patients of the American Society of Anesthesiologists physical status Class I and II who were posted for upper limb surgeries were recruited. Patients were divided into two groups of thirty patients each. Group T (tramadol) received 20 ml of 0.5% levobupivacaine with 100 mg tramadol, and Group D (dexamethasone) received 20 ml of 0.5% levobupivacaine with 8 mg dexamethasone under ultrasound guidance. Sensory and motor block assessment was done every 2 min until the development of complete sensory and motor block till 45 min. Verbal numerical rating scale score was assessed in postoperative ward at regular intervals. Patients were followed up to check for any residual neurological deficits. Results: There was no statistical difference in demographic data between the two groups. The onset time of sensory and motor blockade shows no significant difference between groups. The mean time duration of motor blockade in Group T was 764.63 min and for Group D was 1150.27 min which was statistically significant (P < 0.05). The duration of analgesia in Group D was 1300.83 min and in Group T was 820.47 min which was statistically significant (P < 0.05). Side effects such as nausea, vomiting, pruritis, hypoxemia, and long-term neurological deficits were not reported in any of the patients in either group. Conclusion: Dexamethasone 8 mg as an adjuvant to 0.5% levobupivacaine for supraclavicular brachial plexus block using ultrasound guidance increases the duration of analgesia in comparison to 100 mg tramadol and provides excellent postoperative pain-free period without any neurological deficits.
- Open Access
- 1 January 2017
- Published by Medknow in Anesthesia: Essays and Researches
- Vol. 11 (4) , 934-939
A comparative study of postoperative analgesia provided by ultrasound-guided transversus abdominis plane block using two concentrations of bupivacaine in patients undergoing inguinal hernia repair
Background: Pain after open inguinal hernia surgery can be moderate to severe and is known to prolong hospital stay and delay return to normal daily activities. Settings: A randomized controlled trial conducted in the Department of Anesthesiology in a tertiary care hospital. Aims and Objectives: To compare the efficacy of postoperative analgesia provided by equal volumes of 0.125% and 0.25% bupivacaine administered in an ultrasound (US)-guided transversus abdominis plane (TAP) block in patients undergoing unilateral inguinal hernia repair. Materials and Methods: After obtaining Institutional Ethics Committee approval and informed consent, sixty patients posted for inguinal hernia repair were recruited. Randomization was done using a sealed envelope technique. Patients were divided into two groups; Group 0.125 received 20 ml of 0.125% bupivacaine and Group 0.25 received 20 ml of 0.25% bupivacaine through US-guided TAP block at the end of surgery. Visual analog scale (VAS) scores and duration of analgesia were recorded. Results: There was no significant difference in the VAS scores among both groups. The duration of analgesia provided by 0.25% bupivacaine was significantly longer than that provided by 0.125% (Group 0.125 - 355.67 ± 118.88 min and Group 0.25 - 635.73 ± 195.58 min; P < 0.05). No complications were noted in both groups. Conclusion: The duration of analgesia provided by 0.25% bupivacaine was significantly longer than that provided by 0.125% bupivacaine through US-guided TAP block in inguinal hernia repair.
- 1 January 2017
- Published by Medknow in Anesthesia: Essays and Researches
- Vol. 11 (4) , 934-939
Open AccessA comparative study of postoperative analgesia provided by ultrasound-guided transversus abdominis plane block using two concentrations of bupivacaine in patients undergoing inguinal hernia repair
Background: Pain after open inguinal hernia surgery can be moderate to severe and is known to prolong hospital stay and delay return to normal daily activities. Settings: A randomized controlled trial conducted in the Department of Anesthesiology in a tertiary care hospital. Aims and Objectives: To compare the efficacy of postoperative analgesia provided by equal volumes of 0.125% and 0.25% bupivacaine administered in an ultrasound (US)-guided transversus abdominis plane (TAP) block in patients undergoing unilateral inguinal hernia repair. Materials and Methods: After obtaining Institutional Ethics Committee approval and informed consent, sixty patients posted for inguinal hernia repair were recruited. Randomization was done using a sealed envelope technique. Patients were divided into two groups; Group 0.125 received 20 ml of 0.125% bupivacaine and Group 0.25 received 20 ml of 0.25% bupivacaine through US-guided TAP block at the end of surgery. Visual analog scale (VAS) scores and duration of analgesia were recorded. Results: There was no significant difference in the VAS scores among both groups. The duration of analgesia provided by 0.25% bupivacaine was significantly longer than that provided by 0.125% (Group 0.125 - 355.67 ± 118.88 min and Group 0.25 - 635.73 ± 195.58 min; P < 0.05). No complications were noted in both groups. Conclusion: The duration of analgesia provided by 0.25% bupivacaine was significantly longer than that provided by 0.125% bupivacaine through US-guided TAP block in inguinal hernia repair.
- Open Access
- 1 January 2013
- Published by Medknow in Anesthesia: Essays and Researches
- Vol. 7 (3) , 302-6
Sugammadex: A revolutionary drug in neuromuscular pharmacology
Sugammadex (ORG 25969) is a unique neuromuscular reversal drug; a novel cyclodextrin, the first in a new class of selective relaxant binding agents, which reverse neuromuscular blockade (NMB) with the aminosteroid non-depolarizing muscle relaxants rocuronium and vecuronium. Sugammadex can reverse moderate or deep NMB. The clinical use of sugammadex promises to eliminate many of the shortcomings in current anesthetic practice with regard to antagonism of rocuronium and other aminosteroid muscle relaxants.
- 1 January 2013
- Published by Medknow in Anesthesia: Essays and Researches
- Vol. 7 (3) , 302-6
Open AccessSugammadex: A revolutionary drug in neuromuscular pharmacology
Sugammadex (ORG 25969) is a unique neuromuscular reversal drug; a novel cyclodextrin, the first in a new class of selective relaxant binding agents, which reverse neuromuscular blockade (NMB) with the aminosteroid non-depolarizing muscle relaxants rocuronium and vecuronium. Sugammadex can reverse moderate or deep NMB. The clinical use of sugammadex promises to eliminate many of the shortcomings in current anesthetic practice with regard to antagonism of rocuronium and other aminosteroid muscle relaxants.
- Open Access
- 1 January 2013
- Published by Medknow in Saudi Journal of Anaesthesia
- Vol. 7 (3) , 322-6
Tapentadol hydrochloride: A novel analgesic
Tapentadol is a novel, centrally acting analgesic with dual mechanism of action, combining mu-opioid receptor agonism with noradrenaline reuptake inhibition in the same molecule. It has an improved side effect profile when compared to opioids and nonsteroidal anti-inflammatory drugs. The dual mechanism of action makes Tapentadol a useful analgesic to treat acute, chronic, and neuropathic pain.
- 1 January 2013
- Published by Medknow in Saudi Journal of Anaesthesia
- Vol. 7 (3) , 322-6
Open AccessTapentadol hydrochloride: A novel analgesic
Tapentadol is a novel, centrally acting analgesic with dual mechanism of action, combining mu-opioid receptor agonism with noradrenaline reuptake inhibition in the same molecule. It has an improved side effect profile when compared to opioids and nonsteroidal anti-inflammatory drugs. The dual mechanism of action makes Tapentadol a useful analgesic to treat acute, chronic, and neuropathic pain.